Japan: Novartis gets Government nod for cancer treatment Kymriah at cost of $305800
Kymriah works by removing disease-fighting T-cells from individual patients, modifying them to attack cancer, and then re-infusing them back into the patients.
TOKYO: A Japanese government panel approved Novartis' cancer treatment Kymriah at a price of 33.5 million yen ($305,800) on Wednesday, marking the entry of so-called CAR-T therapy in the country.
Read Also: Novartis recalls three lots of Promacta due to potential peanut contamination
The Swiss drugmaker aims to use the one-time personalised therapy in Japan for children and young people with acute lymphoblastic leukaemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).
Kymriah works by removing disease-fighting T-cells from individual patients, modifying them to attack cancer, and then re-infusing them back into the patients.
Read Also: Novartis to fight US price-fixing claims against Sandoz unit
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd